Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer.

[1]  S. Cannistra.  Cancer of the ovary. , 1993, The New England journal of medicine.

[2]  E. Venkatraman,et al.  Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Jähne.  Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei (Br J Surg 2001; 88: 458–63) , 2001, The British journal of surgery.

[4]  E. Hager,et al.  Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer , 2001, International Journal of Gynecologic Cancer.

[5]  M. Markman.  Intraperitoneal chemotherapy is appropriate first line therapy for patients with optimally debulked ovarian cancer. , 2001, Critical reviews in oncology/hematology.

[6]  N. Santoro,et al.  Cytoreductive Surgery Followed by Intraperitoneal Hyperthermic Perfusion in the Treatment of Recurrent Epithelial Ovarian Cancer: A Phase II Clinical Study , 2001, Tumori.

[7]  G. Keszler,et al.  Differences in thermostability of thymidine kinase isoenzymes in normal ovary and ovarian carcinoma. , 2001, Anticancer research.

[8]  M. Dewhirst,et al.  Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. , 2001, Cancer research.

[9]  F. van Coevorden,et al.  Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei , 2001, The British journal of surgery.

[10]  B. Loggie,et al.  Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  J. Beijnen,et al.  Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[12]  J. Vermorken.  The role of intraperitoneal chemotherapy in epithelial ovarian cancer. , 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[13]  J. Berek,et al.  Intraperitoneal α-Interferon Alternating with Cisplatin in Residual Ovarian Carcinoma: A Phase II Gynecologic Oncology Group Study , 1999 .

[14]  S. Fujimoto,et al.  Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma , 1999, Cancer.

[15]  E. Trimble,et al.  A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer , 1999, Cancer Chemotherapy and Pharmacology.

[16]  E. Venkatraman,et al.  A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment. , 1998, Gynecologic oncology.

[17]  S. Fujimoto,et al.  Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery , 1997, Cancer.

[18]  M. Jones,et al.  Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy. , 1993, Gynecologic Oncology.

[19]  S. Cannistra.  Medical progress : cancer of the ovary , 1993 .

[20]  C. Perez,et al.  Principles and Practice of Gynecologic Oncology , 1992 .

[21]  J W Hunt,et al.  Differential thermal sensitivity of tumour and normal tissue microvascular response during hyperthermia. , 1992, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[22]  P. Saigo,et al.  Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. , 1991, Gynecologic oncology.

[23]  Y. Takano,et al.  Apoptosis induced by mild hyperthermia in human and murine tumour cell lines: A study using electron microscopy and DNA gel electrophoresis , 1991, The Journal of pathology.

[24]  J. Mcvie,et al.  Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. , 1989, Cancer research.

[25]  Jonathan S. Berek,et al.  Practical gynecologic oncology , 1989 .

[26]  J. Cain,et al.  Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factors. , 1988, American journal of obstetrics and gynecology.

[27]  N. Hacker,et al.  Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status. , 1984, Obstetrics and gynecology.

[28]  R K Jain,et al.  Differential response of normal and tumor microcirculation to hyperthermia. , 1984, Cancer research.

[29]  J. Doroshow,et al.  Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. , 1979, Cancer research.